vix.ing · top · new · best · stats · spec

Yoo‐Na Kim

  1. Randomized, two‐arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR‐mutated, platinum‐resistant ovarian cancer: A substudy of KGOG 3045
    2023/08/21 by Yoo‐Na Kim, Je‐Gun Joung, Eunhyang Park +9 · 5 citations
    Medicine · #PARP inhibition in cancer therapy #Ovarian cancer diagnosis and treatment